Skip to main content

Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform

Written by Customer Service on . Posted in Public Companies.

West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) — Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform.

BioStem Technologies will utilize Terminal1’s integrated suite of shareholder intelligence, investor communications, and digital investor relations tools, giving the company a centralized platform to better understand its shareholder base, communicate with investors, and measure engagement across its investor ecosystem.

The addition of BioStem Technologies represents another step in Terminal1’s continued expansion as public companies increasingly look to consolidate traditionally fragmented investor relations functions into a single system.

“Public companies have historically relied on multiple vendors, disconnected data, and separate platforms to manage their investor ecosystem,” said Wesley De Souza, CDO, Terminal1. “Terminal1 was built to bring those functions together. We’re excited to welcome BioStem Technologies to the platform and continue demonstrating how shareholder data can be transformed into actionable intelligence.”

Through Terminal1, companies can access a growing suite of capabilities including:

  • Shareholder Intelligence — Normalize and analyze shareholder and NOBO data to identify ownership trends, active buyers and sellers, shareholder concentration, geographic distribution, and changes over time.
  • Investor Communications — Manage email and SMS communications from a centralized platform while tracking delivery, engagement, and subscriber activity.
  • IR Website & Analytics — Manage a company’s investor-facing digital presence while measuring investor behavior, traffic sources, engagement, and conversions.
  • Integrated Investor Data — Connect shareholder ownership, communications, and digital engagement to provide management teams with a more complete view of their investor ecosystem.

The platform is designed to provide CEOs, CFOs, investor relations teams, and other public-company executives with greater visibility into not only who owns their stock, but also how investors are interacting with the company.

“Adding BioStem Technologies is another important milestone for Terminal1,” added De Souza. “Our goal is straightforward: give public companies one system to understand their shareholders, communicate with the market, and measure what is actually driving investor engagement.”

Terminal1 continues to expand its public-company customer base as it builds out additional capabilities across shareholder intelligence, communications, analytics, and investor relations infrastructure.

About Terminal1

Terminal1 is an operating system built for public companies. The platform brings together shareholder intelligence, investor communications, IR website infrastructure, and investor analytics within one centralized system.Terminal1 helps public companies better understand their shareholders, engage their investor audience, and turn investor data into actionable insights.

For more information, visit www.terminal1.ai.

About BioStem Technologies, Inc.

(Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.

For more information, visit https://biostemtechnologies.com/.

Media Contact

Terminal1

Sally Pritchard

sally@terminal1.ai

Book a Demo

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.